title: Selective uptake and imaging of aptamer- and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer.
abstract: The purpose of this study was to compare the binding affinity and selective targeting of aptamer- and antibody-coated hollow gold nanospheres (HAuNS) targeted to epidermal growth factor receptors (EGFR). EGFR-targeting aptamers were conjugated to HAuNS (apt-HAuNS) by attaching a thiol-terminated single-stranded DNA to the HAuNS and then adding the complementary RNA targeted to EGFR. Apt-HAuNS was characterized in terms of size, surface charge, absorption, and number of aptamers per particle. The in vivo pharmacokinetics, in vivo biodistribution, and micro-SPECT/CT imaging of (111)In-labeled apt-HAuNS and anti-EGFR antibody (C225)-conjugated HAuNS were evaluated in nude mice bearing highly malignant human OSC-19 oral tumors. (111)In-labeled PEG-HAuNS was used as a control (n = 5/group). Apt-HAuNS did not have an altered absorbance profile or size (λmax = 800 nm; diameter = 55 nm) compared to C225-HAuNS or PEG-HAuNS. The surface charge became more negative upon conjugation of the aptamer (-51.4 vs -19.0 for PEG-HAuNS and -25.0 for C225-HAuNS). The number of aptamers/particle was ∼250. In vitro cell binding and in vivo biodistribution showed selective binding of the apt-HAuNS to EGFR. μSPECT/CT imaging confirmed that there was more tumor uptake of apt-HAuNS than C225-HAuNS. Aptamer is a promising ligand for image-guided delivery of nanoparticles for treatment of tumor cells overexpressing EGFR.
authors.affiliation: Departments of Interventional Radiology, ‡Cancer Systems Imaging, ∥Head and Neck Surgery, and ⊥Imaging Physics, The University of Texas MD Anderson Cancer Center , 1515 Holcombe Boulevard, Houston, Texas 77030, United States.
authors.forename: Marites Pasuelo
authors.initials: MP
authors.lastname: Melancon
authors.forename: Min
authors.initials: M
authors.lastname: Zhou
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.forename: Chiyi
authors.initials: C
authors.lastname: Xiong
authors.forename: Peter
authors.initials: P
authors.lastname: Allen
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Wen
authors.forename: Qian
authors.initials: Q
authors.lastname: Huang
authors.forename: Michael
authors.initials: M
authors.lastname: Wallace
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Myers
authors.forename: R Jason
authors.initials: RJ
authors.lastname: Stafford
authors.forename: Dong
authors.initials: D
authors.lastname: Liang
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Ellington
authors.forename: Chun
authors.initials: C
authors.lastname: Li
mesh_terms: D000818:Animals; D000906:Antibodies / Q000737:chemistry*; D019540:Area Under Curve; D002294:Carcinoma, Squamous Cell / Q000378:metabolism; D004277:DNA, Single-Stranded / Q000737:chemistry; D066246:ErbB Receptors / Q000737:chemistry*; D006046:Gold / Q000737:chemistry*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008024:Ligands; D008297:Male; D053768:Metal Nanoparticles / Q000737:chemistry*; D051379:Mice; D008819:Mice, Nude; D054118:Nanospheres / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D009368:Neoplasm Transplantation; D011092:Polyethylene Glycols / Q000737:chemistry; D011485:Protein Binding; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D000906:Antibodies; D004277:DNA, Single-Stranded; D008024:Ligands; D011092:Polyethylene Glycols; D006046:Gold; D066246:ErbB Receptors
references.citation: Cancer Res. 2011 Oct 1;71(19):6116-21
references.pmid: 21856744
references.citation: Cancer Res. 2010 Apr 15;70(8):3177-88
references.pmid: 20388791
references.citation: Small. 2013 Oct 25;9(20):3477-84
references.pmid: 23609964
references.citation: PLoS One. 2011;6(6):e20299
references.pmid: 21687663
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):876-86
references.pmid: 19188158
references.citation: Acc Chem Res. 2011 Oct 18;44(10):947-56
references.pmid: 21848277
references.citation: Nat Nanotechnol. 2008 Mar;3(3):145-50
references.pmid: 18654486
references.citation: Future Oncol. 2010 Jul;6(7):1117-26
references.pmid: 20624124
references.citation: Can J Ophthalmol. 2005 Jun;40(3):352-68
references.pmid: 15947805
references.citation: Clin Cancer Res. 1995 Nov;1(11):1311-8
references.pmid: 9815926
references.citation: Future Oncol. 2013 Mar;9(3):369-76
references.pmid: 23469972
references.citation: Cancer Res. 2001 Jun 15;61(12):4750-5
references.pmid: 11406547
references.citation: Lasers Med Sci. 2008 Jul;23(3):217-28
references.pmid: 17674122
references.citation: Biomaterials. 2009 Apr;30(10):1928-36
references.pmid: 19131103
references.citation: J Nucl Med. 1990 Jul;31(7):1191-8
references.pmid: 2362198
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2787-99
references.pmid: 12860957
references.citation: Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7
references.pmid: 10068277
references.citation: Cancer Res. 2002 Dec 15;62(24):7350-6
references.pmid: 12499279
references.citation: Br J Pharmacol. 2009 May;157(2):220-33
references.pmid: 19459844
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1730-9
references.pmid: 18566244
references.citation: J Clin Oncol. 1993 Oct;11(10):1873-8
references.pmid: 8410112
references.citation: Semin Radiat Oncol. 2002 Jul;12(3 Suppl 2):11-20
references.pmid: 12174340
references.citation: Cancer Res. 2012 Sep 15;72(18):4777-86
references.pmid: 22865457
references.citation: Curr Opin Chem Biol. 2006 Jun;10(3):282-9
references.pmid: 16621675
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):1815-27
references.pmid: 21350000
references.citation: Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):411-20
references.pmid: 19380367
references.citation: Biomaterials. 2010 Mar;31(9):2617-26
references.pmid: 20036000